Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth - United States, 2008-2011

Morbidity and Mortality Weekly Report

Volumn 61, Issue 38, 2012, Pages 768-771

  Benson, Ruthie ^a   Crowley, Susan A ^b   Dusek, Cristina ^c   Lazaroff, Julie ^d   Onye, Kenneth ^e   Smith, Emily A ^f   Walker, Tanja Y ^f   Schillie, Sarah F ^f   Murphy, Trudy V ^f   Zucker, Jane ^g  

^a Texas Dept of State Health Svcs   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

^c FLORIDA DEPARTMENT OF HEALTH   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN;

ADULT; ARTICLE; BLOOD; DISEASE TRANSMISSION; FEMALE; HEPATITIS B; HUMAN; IMMUNOLOGY; INFANT; MALE; NEWBORN; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; SEROLOGY; UNITED STATES; VERTICAL TRANSMISSION;

ADULT; FEMALE; GUIDELINE ADHERENCE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; POST-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEROLOGIC TESTS; UNITED STATES; YOUNG ADULT;

EID: 84867277302     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The National Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics 2012;129:609-16.
2. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995; 274:1201-8.
3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105:94-8.
4. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR 2005; 54(No. RR-16).
5. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program. Pediatr Infect Dis J 1996;15:535-40.
6. Euler GL, Copeland JR, Rangel MC, Williams WW. Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. Pediatr Infec Dis J 2003;22:123-9.
7. Fischer G, Wang S, Ahring S, et al. An investigation of perinatal hepatitis B virus infections among a high risk population: the delivery hospital as a safety net. Pediatr Infec Dis J 2009;28:593-7.
8. Weintraub Z, Khamaysi N, Elena H, Gershtein V, Orenstein L, Lahat N. Transient surface antigenemia in newborn infants vaccinated with Engerix B: occurrence and duration. Pediatr Infec Dis J 1994;13:931-3.
9. Niu MT, Targonski PV, Stoll BJ, Albert GP, Margolis HS. Prevention of perinatal transmission of the hepatitis B virus: outcome of infants in a community prevention program. Am J Dis Child 1992;146:793-6.
10. Euler GL, Copeland J, Williams WW. Impact of four urban perinatal hepatitis B prevention programs on screening and vaccination of infants and household members. Am J Epidemiol 2003;157:747-53.